Partnerships
>> Leadership >> Partnerships >> News

World-Class Partnerships
Ativa develops strong partnerships with innovative biomarker developers and technology companies to create products with global impact and reach through the sales and marketing channels of our distribution partners.

As part of this, we're proud to be the exclusive global licensee of miniaturized flow cytometry technology from Honeywell International Inc., the $77 billion global leader in sensor technologies. Ativa has adopted this core technology and produced a several functional prototypes that have performance characteristics similar to market IVD products.

This technology partnership with Honeywell granted Ativa exclusive licensing rights for over 60 patents.

Ativa is also exploring projects with biomarker development partners to integrate novel content with our micro-lab platform. If you're interested in learning more about the opportunities to partner with us, please contact Ativa today.




Analyzer and Test Cards
How it works
Features/Benefits
Ativa Leadership
Ativa Partnerships
Ativa News
Terms and Conditions
Privacy
Ativa Medical Corporation
1000 Westgate Drive, Suite 100
St. Paul, Minnesota 55114 612.293.3993 Direct
© Ativa Medical Corporation 2017 All rights Reserved
 
This device has not been evaluated, cleared or approved for use by the FDA, and is not for sale in the US. Safety and effectiveness have not been established.


All statements that address expectations or projections about the future, including statements about product development, market position, and financial results, are forward-looking statements. Forward-looking statements can be identified by words like "expect," "may," "could," "believe," "would," "might," "anticipates," and similar expressions. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. We undertake no obligation to update any forward-looking statements.